BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 2015;33:1000-7. [PMID: 25667274 DOI: 10.1200/JCO.2014.58.2007] [Cited by in Crossref: 156] [Cited by in F6Publishing: 77] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Sridhara R, He K, Nie L, Shen Y, Tang S. Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy. Statistics in Biopharmaceutical Research 2015;7:348-56. [DOI: 10.1080/19466315.2015.1094673] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Polo V, Pasello G, Frega S, Favaretto A, Koussis H, Conte P, Bonanno L. Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. Oncotarget 2016;7:25050-63. [PMID: 26933818 DOI: 10.18632/oncotarget.7732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Patel JN. Lessons in practicing cancer genomics and precision medicine. Expert Review of Precision Medicine and Drug Development 2018;3:287-98. [DOI: 10.1080/23808993.2018.1526081] [Reference Citation Analysis]
4 Amaral T, Schulze M, Sinnberg T, Nieser M, Martus P, Battke F, Garbe C, Biskup S, Forschner A. Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy? Cancers (Basel) 2020;12:E1101. [PMID: 32354124 DOI: 10.3390/cancers12051101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Blucher AS, Choonoo G, Kulesz-Martin M, Wu G, McWeeney SK. Evidence-Based Precision Oncology with the Cancer Targetome. Trends Pharmacol Sci 2017;38:1085-99. [PMID: 28964549 DOI: 10.1016/j.tips.2017.08.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
6 Shahid M, Choi TG, Nguyen MN, Matondo A, Jo YH, Yoo JY, Nguyen NN, Yun HR, Kim J, Akter S, Kang I, Ha J, Maeng CH, Kim SY, Lee JS, Kim J, Kim SS. An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer. Oncotarget 2016;7:86561-72. [PMID: 27863408 DOI: 10.18632/oncotarget.13357] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
7 Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, Lester RT, Thorlund K, Mills EJ. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 2019;20:572. [PMID: 31533793 DOI: 10.1186/s13063-019-3664-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 21.0] [Reference Citation Analysis]
8 Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. J Clin Oncol 2017;35:271-3. [PMID: 27893325 DOI: 10.1200/JCO.2016.69.9751] [Cited by in Crossref: 76] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
9 Peguero J, Sohal DPS, O'Neil BH, Safran H, Kelly K, Grilley-Olson JE, Subbiah V, Nadauld L, Purkayastha D, Stealey E, Ricart AD, Kang BP, Eder JP. Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. JCO Precis Oncol 2019;3:1-10. [PMID: 35100715 DOI: 10.1200/PO.18.00383] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Conlon NT, Kooijman JJ, van Gerwen SJC, Mulder WR, Zaman GJR, Diala I, Eli LD, Lalani AS, Crown J, Collins DM. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. Br J Cancer 2021;124:1249-59. [PMID: 33473169 DOI: 10.1038/s41416-020-01257-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A, Wright K, Cantrell A, Stevenson M, Palmer S. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technol Assess 2021;25:1-228. [PMID: 34990339 DOI: 10.3310/hta25760] [Reference Citation Analysis]
12 Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Oncotarget 2017;8:38389-98. [PMID: 28418920 DOI: 10.18632/oncotarget.16409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
13 Chen N, Lee JJ. Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes. Biom J 2019;61:1219-31. [PMID: 30506747 DOI: 10.1002/bimj.201700275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015;12:511-26. [PMID: 25963091 DOI: 10.1038/nrclinonc.2015.90] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 22.1] [Reference Citation Analysis]
15 Tang YQ, Li ZW, Feng YF, Yang HQ, Hou CL, Geng C, Yang PR, Zhao HM, Wang J. MK2206 attenuates atherosclerosis by inhibiting lipid accumulation, cell migration, proliferation, and inflammation. Acta Pharmacol Sin 2021. [PMID: 34316032 DOI: 10.1038/s41401-021-00729-x] [Reference Citation Analysis]
16 Abbosh PH, McConkey DJ, Plimack ER. Targeting Signaling Transduction Pathways in Bladder Cancer. Curr Oncol Rep 2015;17:58. [PMID: 26472299 DOI: 10.1007/s11912-015-0477-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
17 Cai HY, Yang HS, Shan SC, Lei YY, Zou JY, Zhu Y, Luo HH. A novel signature based on immune-related gene pairs and clinical features to predict prognosis and treatment effect in "driver gene negative" lung adenocarcinoma. Cancer Med 2022. [PMID: 35246970 DOI: 10.1002/cam4.4577] [Reference Citation Analysis]
18 Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Fer N, Sonkin D, Kaur G, Monks A, Malik S, Morris J, Teicher BA. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. J Natl Cancer Inst 2016;108. [PMID: 27247353 DOI: 10.1093/jnci/djw122] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 14.0] [Reference Citation Analysis]
19 Catenacci DV. Expansion platform type II: testing a treatment strategy. Lancet Oncol 2015;16:1276-8. [PMID: 26342235 DOI: 10.1016/S1470-2045(15)00224-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
20 Nimmagadda S. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers (Basel) 2020;12:E3173. [PMID: 33137949 DOI: 10.3390/cancers12113173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
21 Köhn L, Johansson M, Grankvist K, Nilsson J. Liquid biopsies in lung cancer-time to implement research technologies in routine care? Ann Transl Med 2017;5:278. [PMID: 28758104 DOI: 10.21037/atm.2017.04.12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
22 Weichert W. [Limitations, pitfalls and perspectives of diagnostic massive parallel sequencing efforts in oncology]. Pathologe 2015;36 Suppl 2:162-6. [PMID: 26391247 DOI: 10.1007/s00292-015-0073-4] [Reference Citation Analysis]
23 Li P, Li B, Shi Y, Zhang F, Shen S, Li X. [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung 
Adenocarcinoma]. Zhongguo Fei Ai Za Zhi 2019;22:137-42. [PMID: 30909992 DOI: 10.3779/j.issn.1009-3419.2019.03.03] [Reference Citation Analysis]
24 Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-cuaran S. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 2022;103:102335. [DOI: 10.1016/j.ctrv.2021.102335] [Reference Citation Analysis]
25 An R, Wang Y, Voeller D, Gower A, Kim IK, Zhang YW, Giaccone G. CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. Oncotarget 2016;7:29199-210. [PMID: 27078848 DOI: 10.18632/oncotarget.8638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Villanueva A. Selected summary for the 2015 Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE). Hepat Oncol 2016;3:5-8. [PMID: 30191022 DOI: 10.2217/hep.15.37] [Reference Citation Analysis]
27 Masciale V, Banchelli F, Grisendi G, D'Amico R, Maiorana A, Stefani A, Morandi U, Dominici M, Aramini B. New Perspectives in Different Gene Expression Profiles for Early and Locally Advanced Non-Small Cell Lung Cancer Stem Cells. Front Oncol 2021;11:613198. [PMID: 33868998 DOI: 10.3389/fonc.2021.613198] [Reference Citation Analysis]
28 Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 2015;15:747-56. [PMID: 26536825 DOI: 10.1038/nrc4015] [Cited by in Crossref: 330] [Cited by in F6Publishing: 287] [Article Influence: 47.1] [Reference Citation Analysis]
29 Siden EG, Park JJ, Zoratti MJ, Dron L, Harari O, Thorlund K, Mills EJ. Reporting of master protocols towards a standardized approach: A systematic review. Contemp Clin Trials Commun 2019;15:100406. [PMID: 31334382 DOI: 10.1016/j.conctc.2019.100406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
30 Senft D, Leiserson MDM, Ruppin E, Ronai ZA. Precision Oncology: The Road Ahead. Trends Mol Med 2017;23:874-98. [PMID: 28887051 DOI: 10.1016/j.molmed.2017.08.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 14.6] [Reference Citation Analysis]
31 Wathieu H, Issa NT, Fernandez AI, Mohandoss M, Tiek DM, Franke JL, Byers SW, Riggins RB, Dakshanamurthy S. Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. Oncotarget 2017;8:92926-42. [PMID: 29190967 DOI: 10.18632/oncotarget.21669] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018;24:6248-6256. [PMID: 30348637 DOI: 10.1158/1078-0432.ccr-18-1128] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
33 Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016;1:e87062. [PMID: 27882345 DOI: 10.1172/jci.insight.87062] [Cited by in Crossref: 202] [Cited by in F6Publishing: 194] [Article Influence: 33.7] [Reference Citation Analysis]
34 Nogova L, Mattonet C, Scheffler M, Taubert M, Gardizi M, Sos ML, Michels S, Fischer RN, Limburg M, Abdulla DSY, Persigehl T, Kobe C, Merkelbach-Bruse S, Franklin J, Backes H, Schnell R, Behringer D, Kaminsky B, Eichstaedt M, Stelzer C, Kinzig M, Sörgel F, Tian Y, Junge L, Suleiman AA, Frechen S, Rokitta D, Ouyang D, Fuhr U, Buettner R, Wolf J. Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Med 2020;9:4991-5007. [PMID: 32436621 DOI: 10.1002/cam4.3131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Huang WC, Yadav VK, Cheng WH, Wang CH, Hsieh MS, Huang TY, Lin SF, Yeh CT, Kuo KT. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers (Basel) 2021;13:6005. [PMID: 34885115 DOI: 10.3390/cancers13236005] [Reference Citation Analysis]
36 Zhang Y, Mai H, Guo G, Bi G, Hao G, Li Y, Wang X, Cheng L, Wang J, Dong R, Liu Z, Chen L, Qu H. Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma. Oncotarget 2018;9:14109-23. [PMID: 29581831 DOI: 10.18632/oncotarget.23881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Cunanan KM, Iasonos A, Shen R, Begg CB, Gönen M. An efficient basket trial design. Stat Med 2017;36:1568-79. [PMID: 28098411 DOI: 10.1002/sim.7227] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
38 Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel) 2015;7:930-49. [PMID: 26018876 DOI: 10.3390/cancers7020816] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 9.1] [Reference Citation Analysis]
39 Schmidt KT, Chau CH, Price DK, Figg WD. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol 2016;56:1484-99. [PMID: 27197880 DOI: 10.1002/jcph.765] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
40 Sun S, Zhang Z. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization. Front Med 2016;10:104-10. [PMID: 26926009 DOI: 10.1007/s11684-016-0432-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
41 Yang X, Zhuo M, Ye X, Bai H, Wang Z, Sun Y, Zhao J, An T, Duan J, Wu M, Wang J. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget 2016;7:20810-24. [PMID: 26989078 DOI: 10.18632/oncotarget.8021] [Cited by in Crossref: 45] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
42 Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shirota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, Arihiro K, Yamamoto M, Unno M, Yamaue H, Weiss MJ, Wolfgang CL, Furukawa T, Nakagama H, Vogelstein B, Kiyono T, Hruban RH, Shibata T. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell. 2016;29:229-240. [PMID: 26806338 DOI: 10.1016/j.ccell.2015.12.012] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 13.2] [Reference Citation Analysis]
43 Heim D, Montavon G, Hufnagl P, Müller KR, Klauschen F. Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers. Genome Med 2018;10:83. [PMID: 30442178 DOI: 10.1186/s13073-018-0591-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017;23:1028-1035. [PMID: 28886003 DOI: 10.1038/nm.4389] [Cited by in Crossref: 145] [Cited by in F6Publishing: 119] [Article Influence: 29.0] [Reference Citation Analysis]
45 Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget 2018;9:6630-43. [PMID: 29464099 DOI: 10.18632/oncotarget.23553] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
46 Wrzeszczynski KO, Felice V, Abhyankar A, Kozon L, Geiger H, Manaa D, London F, Robinson D, Fang X, Lin D, Lamendola-Essel MF, Khaira D, Dikoglu E, Emde AK, Robine N, Shah M, Arora K, Basturk O, Bhanot U, Kentsis A, Mansukhani MM, Bhagat G, Jobanputra V. Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer. J Mol Diagn 2018;20:822-35. [PMID: 30138725 DOI: 10.1016/j.jmoldx.2018.06.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
47 Han J, Liu Y, Yang S, Wu X, Li H, Wang Q. MEK inhibitors for the treatment of non-small cell lung cancer. J Hematol Oncol 2021;14:1. [PMID: 33402199 DOI: 10.1186/s13045-020-01025-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
48 Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 2017;28:34-43. [PMID: 28177494 DOI: 10.1093/annonc/mdw413] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 32.5] [Reference Citation Analysis]
49 Fiore LD, Brophy MT, Turek S, Kudesia V, Ramnath N, Shannon C, Ferguson R, Pyarajan S, Fiore MA, Hornberger J, Lavori P. The VA Point-of-Care Precision Oncology Program: Balancing Access with Rapid Learning in Molecular Cancer Medicine. Biomark Cancer 2016;8:9-16. [PMID: 26949343 DOI: 10.4137/BIC.S37548] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
50 Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J, Lang S, Scharl M, Rogler G. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget 2015;6:42183-96. [PMID: 26544513 DOI: 10.18632/oncotarget.5619] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
51 Cunanan KM, Iasonos A, Shen R, Hyman DM, Riely GJ, Gönen M, Begg CB. Specifying the True- and False-Positive Rates in Basket Trials. JCO Precis Oncol 2017;1:PO. [PMID: 32913969 DOI: 10.1200/PO.17.00181] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget 2015;6:14744-53. [PMID: 26142706 DOI: 10.18632/oncotarget.4539] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
53 Lara PN Jr, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res 2015;21:4321-6. [PMID: 26106072 DOI: 10.1158/1078-0432.CCR-14-3281] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
54 Thomas A, Chen Y, Steinberg SM, Luo J, Pack S, Raffeld M, Abdullaev Z, Alewine C, Rajan A, Giaccone G, Pastan I, Miettinen M, Hassan R. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget 2015;6:11694-703. [PMID: 26028668 DOI: 10.18632/oncotarget.3429] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
55 Zhou N, Zhao J, Huang X, Shen H, Li W, Xu Z, Xia Y. The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis. Transl Cancer Res 2020;9:3634-42. [PMID: 35117726 DOI: 10.21037/tcr.2020.04.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
56 Fang B. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochim Biophys Sin (Shanghai) 2016;48:27-38. [PMID: 26350096 DOI: 10.1093/abbs/gmv090] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
57 Horak P, Fröhling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open 2016;1:e000094. [PMID: 27933214 DOI: 10.1136/esmoopen-2016-000094] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 15.5] [Reference Citation Analysis]
58 Cortinovis D, Abbate M, Bidoli P, Pelizzoni D, Canova S. Interpretation of lung cancer study outcomes. J Thorac Dis 2015;7:E541-7. [PMID: 26716052 DOI: 10.3978/j.issn.2072-1439.2015.11.26] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Mitani Y, Kanai M, Kou T, Kataoka S, Doi K, Matsubara J, Ohashi S, Matsumoto S, Muto M. Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report. BMC Cancer 2020;20:1177. [PMID: 33267781 DOI: 10.1186/s12885-020-07640-4] [Reference Citation Analysis]
60 Abdelraouf F, Sharp A, Maurya M, Mair D, Wotherspoon A, Leary A, Gonzalez de Castro D, Bhosle J, Nassef A, Gaafar T, Popat S, Yap TA, O'Brien M. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. BMC Res Notes 2015;8:688. [PMID: 26581482 DOI: 10.1186/s13104-015-1675-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
61 Davis JS, Prophet E, Peng HL, Lee HY, Tidwell RSS, Lee JJ, Thomas A, Szabo E, Chang S. Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. JNCI Cancer Spectr 2019;3:pkz010. [PMID: 31218274 DOI: 10.1093/jncics/pkz010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol 2016;27:693-9. [PMID: 26802155 DOI: 10.1093/annonc/mdw008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
63 Kim C, Giaccone G. Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design. Ann Transl Med 2016;4:466. [PMID: 28090522 DOI: 10.21037/atm.2016.11.48] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
64 Slosberg ED, Kang BP, Peguero J, Taylor M, Bauer TM, Berry DA, Braiteh F, Spira A, Meric-Bernstam F, Stein S, Piha-Paul SA, Salvado A. Signature program: a platform of basket trials. Oncotarget 2018;9:21383-95. [PMID: 29765547 DOI: 10.18632/oncotarget.25109] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
65 El Naqa I, Kerns SL, Coates J, Luo Y, Speers C, West CML, Rosenstein BS, Ten Haken RK. Radiogenomics and radiotherapy response modeling. Phys Med Biol 2017;62:R179-206. [PMID: 28657906 DOI: 10.1088/1361-6560/aa7c55] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
66 Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, Mukai K, Orazi A, Ströbel P. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol 2015;10:1383-95. [PMID: 26295375 DOI: 10.1097/JTO.0000000000000654] [Cited by in Crossref: 226] [Cited by in F6Publishing: 117] [Article Influence: 37.7] [Reference Citation Analysis]
67 Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov 2021;11:308-25. [PMID: 33234578 DOI: 10.1158/2159-8290.CD-20-1408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
68 Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. J Clin Oncol 2022;:JCO2101455. [PMID: 35073148 DOI: 10.1200/JCO.21.01455] [Reference Citation Analysis]
69 Bizzarri M, Fedeli V, Monti N, Cucina A, Jalouli M, Alwasel SH, Harrath AH. Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes. EPMA J 2021;:1-14. [PMID: 34642594 DOI: 10.1007/s13167-021-00254-1] [Reference Citation Analysis]
70 Kumar M, Ernani V, Owonikoko TK. Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol Aspects Med 2015;45:55-66. [PMID: 26187108 DOI: 10.1016/j.mam.2015.06.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
71 Testa U, Castelli G, Pelosi E. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers (Basel) 2018;10:E248. [PMID: 30060526 DOI: 10.3390/cancers10080248] [Cited by in Crossref: 97] [Cited by in F6Publishing: 108] [Article Influence: 24.3] [Reference Citation Analysis]
72 Ou FS, An MW, Ruppert AS, Mandrekar SJ. Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies. JCO Precis Oncol 2019;3. [PMID: 32190807 DOI: 10.1200/po.19.00051] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 2016;27:1068-74. [PMID: 27045102 DOI: 10.1093/annonc/mdw073] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
74 Gittings LM, Sattler R. Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies. Fac Rev 2020;9:12. [PMID: 33659944 DOI: 10.12703/b/9-12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Tsang H, Addepalli K, Davis SR. Resources for Interpreting Variants in Precision Genomic Oncology Applications. Front Oncol 2017;7:214. [PMID: 28975082 DOI: 10.3389/fonc.2017.00214] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
76 Sherman M. Design and Endpoints of Clinical Trials, Current and Future. Dig Dis Sci 2019;64:1050-7. [PMID: 30830522 DOI: 10.1007/s10620-019-05541-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2:e000279. [PMID: 29209536 DOI: 10.1136/esmoopen-2017-000279] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
78 Wilson JL, Altman RB. Biomarkers: Delivering on the expectation of molecularly driven, quantitative health. Exp Biol Med (Maywood). 2018;243:313-322. [PMID: 29199461 DOI: 10.1177/1535370217744775] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
79 Szklener K, Michalski A, Żak K, Piwoński M, Mańdziuk S. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions. Cells 2022;11:1338. [DOI: 10.3390/cells11081338] [Reference Citation Analysis]
80 Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. Contemp Clin Trials Commun 2018;12:1-8. [PMID: 30182068 DOI: 10.1016/j.conctc.2018.08.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
81 Jo U, Murai Y, Takebe N, Thomas A, Pommier Y. Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. Cancers (Basel) 2021;13:4601. [PMID: 34572827 DOI: 10.3390/cancers13184601] [Reference Citation Analysis]
82 Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, Caulfield TR, Kuranz-Blake M, Chitta K, Wang X, Asmann Y, Hudec R, Springer W, Ailawadhi S, Chanan-Khan A. Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 2017;7:e565. [PMID: 28548645 DOI: 10.1038/bcj.2017.40] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
83 Parisot JP, Thorne H, Fellowes A, Doig K, Lucas M, McNeil JJ, Doble B, Dobrovic A, John T, James PA, Lipton L, Ashley D, Hayes T, McMurrick P, Richardson G, Lorgelly P, Fox SB, Thomas DM. "Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. J Pers Med 2015;5:354-69. [PMID: 26529019 DOI: 10.3390/jpm5040354] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
84 Mak RH, Hermann G, Aerts HJ, Baldini EH, Chen AB, Kozono D, Rabin MS, Swanson SJ, Chen Y, Catalano P, Johnson BE, Jänne PA. Outcomes by EGFR , KRAS , and ALK Genotype After Combined Modality Therapy for Locally Advanced Non–Small-Cell Lung Cancer. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00219] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
85 Joffe E, Iasonos A, Younes A. Clinical Trials in the Genomic Era. J Clin Oncol 2017;35:1011-7. [PMID: 28297622 DOI: 10.1200/JCO.2016.70.8891] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
86 Créquit P, Trinquart L, Ravaud P. Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor. BMJ Open 2016;6:e011841. [PMID: 27489157 DOI: 10.1136/bmjopen-2016-011841] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
87 Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ; Cancer Genome Atlas Network. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 2018;33:244-258.e10. [PMID: 29438696 DOI: 10.1016/j.ccell.2018.01.003] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 24.0] [Reference Citation Analysis]
88 Donovan MJ, Cordon-Cardo C. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. Mol Diagn Ther 2017;21:115-23. [PMID: 28000172 DOI: 10.1007/s40291-016-0249-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
89 Sabir SH, Krishnamurthy S, Gupta S, Mills GB, Wei W, Cortes AC, Mills Shaw KR, Luthra R, Wallace MJ. Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. PLoS One 2017;12:e0189651. [PMID: 29281680 DOI: 10.1371/journal.pone.0189651] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
90 Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, Richter C, Zips D, Bortfeld T. Radiation oncology in the era of precision medicine. Nat Rev Cancer 2016;16:234-49. [PMID: 27009394 DOI: 10.1038/nrc.2016.18] [Cited by in Crossref: 356] [Cited by in F6Publishing: 326] [Article Influence: 59.3] [Reference Citation Analysis]
91 Xuan Y, Bateman NW, Gallien S, Goetze S, Zhou Y, Navarro P, Hu M, Parikh N, Hood BL, Conrads KA, Loosse C, Kitata RB, Piersma SR, Chiasserini D, Zhu H, Hou G, Tahir M, Macklin A, Khoo A, Sun X, Crossett B, Sickmann A, Chen YJ, Jimenez CR, Zhou H, Liu S, Larsen MR, Kislinger T, Chen Z, Parker BL, Cordwell SJ, Wollscheid B, Conrads TP. Standardization and harmonization of distributed multi-center proteotype analysis supporting precision medicine studies. Nat Commun 2020;11:5248. [PMID: 33067419 DOI: 10.1038/s41467-020-18904-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]